Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1995 Apr;33(4):924–929. doi: 10.1128/jcm.33.4.924-929.1995

Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa.

M C Jaffar-Bandjee 1, A Lazdunski 1, M Bally 1, J Carrère 1, J P Chazalette 1, C Galabert 1
PMCID: PMC228069  PMID: 7790462

Abstract

Secretion of Pseudomonas aeruginosa elastase, exotoxin A, and alkaline protease in sputum during bronchopulmonary exacerbations was examined in 18 cystic fibrosis patients chronically infected with this microorganism. The patients were studied during one or several exacerbation periods necessitating hospitalizations of 12 to 20 days. In all cases, P. aeruginosa was present in bronchial secretions at admission and was not eradicated after treatment. The P. aeruginosa density decreased significantly after antibiotic therapy but remained greater than 10(6) CFU/g of sputum in most cases. Significant amounts of P. aeruginosa exoproteins were measured in total homogenized bronchial secretions by immunoenzymatic assays. The detection of higher levels of exoproteins at admission, the significant decrease after treatment, and the absence of exoproteins during intercrisis phases constituted arguments for a renewal of virulence of P. aeruginosa during exacerbations. Nevertheless, the concomitant changes in bacteria load and the triggering of the inflammatory process and immune complex formation could also contribute to pulmonary exacerbations.

Full Text

The Full Text of this article is available as a PDF (226.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amitani R., Wilson R., Rutman A., Read R., Ward C., Burnett D., Stockley R. A., Cole P. J. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol. 1991 Jan;4(1):26–32. doi: 10.1165/ajrcmb/4.1.26. [DOI] [PubMed] [Google Scholar]
  2. Beaudry P. H., Marks M. I., McDougall D., Desmond K., Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? J Pediatr. 1980 Jul;97(1):144–147. doi: 10.1016/s0022-3476(80)80155-7. [DOI] [PubMed] [Google Scholar]
  3. Berger M. Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? Clin Rev Allergy. 1991 Spring-Summer;9(1-2):119–142. doi: 10.1007/978-1-4612-0475-6_8. [DOI] [PubMed] [Google Scholar]
  4. Boukadida J., De Montalembert M., Lenoir G., Scheinmann P., Véron M., Berche P. Molecular epidemiology of chronic pulmonary colonisation by Pseudomonas aeruginosa in cystic fibrosis. J Med Microbiol. 1993 Jan;38(1):29–33. doi: 10.1099/00222615-38-1-29. [DOI] [PubMed] [Google Scholar]
  5. Döring G., Buhl V., Høiby N., Schiøtz P. O., Botzenhart K. Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from sputum of cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand C. 1984 Oct;92(5):307–312. doi: 10.1111/j.1699-0463.1984.tb00092.x. [DOI] [PubMed] [Google Scholar]
  6. Döring G., Goldstein W., Botzenhart K., Kharazmi A., Schiøtz P. O., Høiby N., Dasgupta M. Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease. Clin Exp Immunol. 1986 Jun;64(3):597–605. [PMC free article] [PubMed] [Google Scholar]
  7. Döring G., Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun. 1983 Oct;42(1):197–201. doi: 10.1128/iai.42.1.197-201.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Döring G., Obernesser H. J., Botzenhart K., Flehmig B., Høiby N., Hofmann A. Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis. 1983 Apr;147(4):744–750. doi: 10.1093/infdis/147.4.744. [DOI] [PubMed] [Google Scholar]
  9. Girard F., Tournier J. M., Polu J. M., Puchelle E., Beck G., Sandoul P. Ultrasonic method of sputum homogenization and its application in the study of the enzymic content of sputum. Clin Chim Acta. 1981 Jun 2;113(1):105–109. doi: 10.1016/0009-8981(81)90446-0. [DOI] [PubMed] [Google Scholar]
  10. Grimwood K., Semple R. A., Rabin H. R., Sokol P. A., Woods D. E. Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. Pediatr Pulmonol. 1993 Mar;15(3):135–139. doi: 10.1002/ppul.1950150302. [DOI] [PubMed] [Google Scholar]
  11. Hammerschlag M. R., Harding L., Macone A., Smith A. L., Goldmann D. A. Bacteriology of sputum in cystic fibrosis: evaluation of dithiothreitol as a mucolytic agent. J Clin Microbiol. 1980 Jun;11(6):552–557. doi: 10.1128/jcm.11.6.552-557.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hoiby N. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):541–550. [PubMed] [Google Scholar]
  13. Hoiby N., Flensborg E. W., Beck B., Friis B., Jacobsen S. V., Jacobsen L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis. 1977 Apr;58(2):65–79. [PubMed] [Google Scholar]
  14. Hyatt A. C., Chipps B. E., Kumor K. M., Mellits E. D., Lietman P. S., Rosenstein B. J. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr. 1981 Aug;99(2):307–314. doi: 10.1016/s0022-3476(81)80486-6. [DOI] [PubMed] [Google Scholar]
  15. Høiby N., Koch C. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax. 1990 Nov;45(11):881–884. doi: 10.1136/thx.45.11.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jaffar-Bandjee M. C., Carrere J., Lazdunski A., Guy-Crotte O., Galabert C. Direct double antibody sandwich immunoassay for Pseudomonas aeruginosa elastase. J Immunol Methods. 1993 Aug 26;164(1):27–32. doi: 10.1016/0022-1759(93)90272-9. [DOI] [PubMed] [Google Scholar]
  17. Jaffar-Bandjee M. C., Carrère J., Bally M., Guy-Crotte O., Galabert C. Immunoenzymometric assays for alkaline protease and exotoxin A from Pseudomonas aeruginosa: development and use in detecting exoproteins in clinical isolates from patients with cystic fibrosis. Eur J Clin Chem Clin Biochem. 1994 Dec;32(12):893–899. doi: 10.1515/cclm.1994.32.12.893. [DOI] [PubMed] [Google Scholar]
  18. Johnson D. A., Carter-Hamm B., Dralle W. M. Inactivation of human bronchial mucosal proteinase inhibitor by Pseudomonas aeruginosa elastase. Am Rev Respir Dis. 1982 Dec;126(6):1070–1073. doi: 10.1164/arrd.1982.126.6.1070. [DOI] [PubMed] [Google Scholar]
  19. Klinger J. D., Straus D. C., Hilton C. B., Bass J. A. Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay. J Infect Dis. 1978 Jul;138(1):49–48. doi: 10.1093/infdis/138.1.49. [DOI] [PubMed] [Google Scholar]
  20. Kobayashi I., Hasegawa M., Nishida M., Goto S. Co-existence of colonies with different serotypes and other biological characteristics in clinical isolates of Pseudomonas aeruginosa. Microbiol Immunol. 1992;36(11):1113–1118. doi: 10.1111/j.1348-0421.1992.tb02115.x. [DOI] [PubMed] [Google Scholar]
  21. Lam J., Chan R., Lam K., Costerton J. W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun. 1980 May;28(2):546–556. doi: 10.1128/iai.28.2.546-556.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McLaughlin F. J., Matthews W. J., Jr, Strieder D. J., Sullivan B., Taneja A., Murphy P., Goldmann D. A. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis. 1983 Mar;147(3):559–567. doi: 10.1093/infdis/147.3.559. [DOI] [PubMed] [Google Scholar]
  23. Morihara K., Tsuzuki H., Harada M., Iwata T. Purification of human plasma alpha 1-proteinase inhibitor and its inactivation by Pseudomonas aeruginosa elastase. J Biochem. 1984 Mar;95(3):795–804. doi: 10.1093/oxfordjournals.jbchem.a134671. [DOI] [PubMed] [Google Scholar]
  24. Moss R. B., Hsu Y. P., Lewiston N. J., Curd J. G., Milgrom H., Hart S., Dyer B., Larrick J. W. Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Am Rev Respir Dis. 1986 Apr;133(4):648–652. doi: 10.1164/arrd.1986.133.4.648. [DOI] [PubMed] [Google Scholar]
  25. Nicas T. I., Iglewski B. H. The contribution of exoproducts to virulence of Pseudomonas aeruginosa. Can J Microbiol. 1985 Apr;31(4):387–392. doi: 10.1139/m85-074. [DOI] [PubMed] [Google Scholar]
  26. Padoan R., Cambisano W., Costantini D., Crossignani R. M., Danza M. L., Trezzi G., Giunta A. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. Pediatr Infect Dis J. 1987 Jul;6(7):648–653. doi: 10.1097/00006454-198707000-00006. [DOI] [PubMed] [Google Scholar]
  27. Pedersen S. S., Møller H., Espersen F., Sørensen C. H., Jensen T., Høiby N. Mucosal immunity to Pseudomonas aeruginosa alginate in cystic fibrosis. APMIS. 1992 Apr;100(4):326–334. [PubMed] [Google Scholar]
  28. Petersen N. T., Høiby N., Mordhorst C. H., Lind K., Flensborg E. W., Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981 Sep;70(5):623–628. doi: 10.1111/j.1651-2227.1981.tb05757.x. [DOI] [PubMed] [Google Scholar]
  29. Prober C. G. The impact of respiratory viral infections in patients with cystic fibrosis. Clin Rev Allergy. 1991 Spring-Summer;9(1-2):87–102. doi: 10.1007/978-1-4612-0475-6_6. [DOI] [PubMed] [Google Scholar]
  30. Regelmann W. E., Elliott G. R., Warwick W. J., Clawson C. C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):914–921. doi: 10.1164/ajrccm/141.4_Pt_1.914. [DOI] [PubMed] [Google Scholar]
  31. Smith A. L., Redding G., Doershuk C., Goldmann D., Gore E., Hilman B., Marks M., Moss R., Ramsey B., Rubio T. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr. 1988 Apr;112(4):547–554. doi: 10.1016/s0022-3476(88)80165-3. [DOI] [PubMed] [Google Scholar]
  32. Suter S., Chevallier I. Proteolytic inactivation of alpha 1-proteinase inhibitor in infected bronchial secretions from patients with cystic fibrosis. Eur Respir J. 1991 Jan;4(1):40–49. [PubMed] [Google Scholar]
  33. Suter S., Schaad U. B., Roux L., Nydegger U. E., Waldvogel F. A. Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis. 1984 Apr;149(4):523–531. doi: 10.1093/infdis/149.4.523. [DOI] [PubMed] [Google Scholar]
  34. Winnie G. B., Cowan R. G. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol. 1991;10(2):92–100. doi: 10.1002/ppul.1950100210. [DOI] [PubMed] [Google Scholar]
  35. Woods D. E., Cryz S. J., Friedman R. L., Iglewski B. H. Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect Immun. 1982 Jun;36(3):1223–1228. doi: 10.1128/iai.36.3.1223-1228.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES